English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Cutaneous melanoma (CM) is a skin tumour derived from abnormal melanocytes that is prone to migrate in the early stage. It accounts for approximately 75% of skin cancerrelated deaths (1). Recently, the incidence of CM is one of the most rapidly increasing among cancers worldwide. The increased incidence varies among populations, ranging from 3% to 7% (2). Studies from Europe and the United States reports increases in the incidence of CM (3,4). The mortality of melanoma has also increased in men older than 65 years. This finding may be attributed to their unique biology and/or an altered host immune response (5). Previously, treatment options were limited by modest response rates in patients with advanced-stage melanoma. Despite targeted therapy and immunotherapy raising the response rate in recent years, the long-term survival rate remains low. Therefore, the discovery of efficient therapeutics will be key for treating CM to improve overall survival. Emodin, extracted from the rhizomes of various Chinese herbal medicines, such as rhubarb, rheum and Original Article

Emodin inhibits the proliferation and migration of B16F10 cells and induces their apoptosis